AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04347174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
Trial: NCT01754805
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT04551534
Drug: DNL201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose(s)
Trial: NCT04551534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose(s)
Trial: NCT03358524
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar capsule manufactured to mimic vitamin E capsule once per day
Trial: NCT02296645
Drug: ZuraPrep
RxNorm normalized name: DuraPrep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT00593190
Drug: Gas SF6 (Sulfur Hexafluoride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONCE
Trial: NCT04578236
Drug: Drug: Standard treatment Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Trial: NCT00859313
Drug: Sufentanil NanoTab PCA System/15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Trial: NCT00212368
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01551511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical step-up approach to the Namisol arm.
Trial: NCT01995188
Drug: DNIB0600A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
Trial: NCT01072604
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One oral dose of new formula Aspirin Prototype 1 under fasting conditions
Trial: NCT01072604
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One oral dose of new formula Aspirin Prototype 2 under fasting conditions
Trial: NCT01072604
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One oral dose of Aspirin Plain Tablet under fasting conditions
Trial: NCT01072604
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One oral dose of Aspirin Dry Granules under fasting conditions
Trial: NCT03417154
Drug: Low dose Cyclophosphamide (CTX) Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
Trial: NCT03417154
Drug: Low dose Cyclophosphamide (CTX) Every 7 Days
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
Trial: NCT00212589
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00212589
Drug: Fluorouracil + folinic acid
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00958516
Drug: LEO 29102 cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 29102 cream in different doses and the cream vehicle
Trial: NCT00135499
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m², D1, 4 cycles
Trial: NCT00135499
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg/m², D1, 4 cycles
Trial: NCT00135499
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m², D1, 4 cycles
Trial: NCT00135499
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m², D1, 4 cycles
Trial: NCT03836261
Drug: Chemoimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
Trial: NCT04200352
Drug: TEV-50717
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets are 6, 9, and 12 mg.
Trial: NCT04371393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
Trial: NCT02162199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
Trial: NCT00452972
Drug: Spinal Anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03818334
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 1000 mg/flask
Trial: NCT04179929
Drug: Pediatric-type of chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
Trial: NCT00673712
Drug: Opioid based analgesia
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN
Trial: NCT00743873
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of 6 cc of saline into injured area
Trial: NCT04217941
Drug: Health Education and practical demonstration of Nasal spray and intranasal ointment
RxNorm normalized name: betamethasone / gentamicin Topical Spray [Betagen brand of Betamethasone and Gentamicin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
Trial: NCT04421027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00065572
Drug: ZD6126
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00065572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00590772
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 2 weeks
Trial: NCT02560545
Drug: Cannabis oil
RxNorm normalized name: Cannabis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis oil 20% THC
Trial: NCT01460043
Drug: Homeopathy
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
Trial: NCT01460043
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
Trial: NCT00036868
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00036868
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00036868
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00337623
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02461407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo p.o. qd
Trial: NCT02873702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules.
Trial: NCT01977482
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
Trial: NCT01977482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet for GSK1278863
Trial: NCT04743986
Drug: Corticosteroid (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/ml triamcinolone in 2 ml 0.5% bupivicaine
Trial: NCT01851603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical diluent to that used for AVL-3288
Trial: NCT01650597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
Trial: NCT00114517
Drug: 17B-estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17B-estradiol 1 mg daily
Trial: NCT03252925
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg/Kg.d, oral
Trial: NCT04396236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00967421
Drug: ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
Trial: NCT00967421
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
Trial: NCT04320589
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ \& β-adrenergic blockers \[Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day \&/or Labetalol (Trandate)200-600 mg/day, ACI \& ACRB e.g. Tritace 2.5-10 mg/day \& Atacand 4-16 mg/day\]
Trial: NCT02563067
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 150 mg once daily
Trial: NCT02563067
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 450 mg once daily
Trial: NCT02563067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT00839319
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg testosterone gel applied transdermally for 10 days
Trial: NCT04323657
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Flu/Cy Lymphodepletion
Trial: NCT00938275
Drug: 0.5g SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment.
Trial: NCT02892916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bolus of an intravenous normal saline solution following induction of anaesthesia.
Trial: NCT01847326
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01416324
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle used to dilute the powder for oral administration.
Trial: NCT01416324
Drug: 0.1 mg GSK2330672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Trial: NCT01416324
Drug: 0.3 mg GSK2330672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Trial: NCT01416324
Drug: 1 mg GSK2330672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Trial: NCT01416324
Drug: 3 mg GSK2330672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Trial: NCT01416324
Drug: 10 mg GSK2330672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Trial: NCT01416324
Drug: 30 mg GSK2330672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Trial: NCT01416324
Drug: 60 mg GSK2330672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Trial: NCT00955916
Drug: CLAG Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The CLAG regimen consisted of: Cladribine, 5 mg/m\^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m\^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
Trial: NCT00955916
Drug: Gleevec®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
Trial: NCT03257319
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient in arm A will receive 1 to 6 injection
Trial: NCT00004669
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03925779
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil sedation
Trial: NCT01041755
Drug: L-ornithine-L-aspartate
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
Trial: NCT01041755
Drug: Lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
Trial: NCT04468997
Drug: Drug 601
RxNorm normalized name: ethanol 0.601 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
Trial: NCT04468997
Drug: Drug 601
RxNorm normalized name: ethanol 0.601 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once;
Trial: NCT04468997
Drug: Drug 601
RxNorm normalized name: ethanol 0.601 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once;
Trial: NCT04468997
Drug: Drug 601
RxNorm normalized name: ethanol 0.601 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
Trial: NCT04468997
Drug: Drug 601
RxNorm normalized name: ethanol 0.601 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
Trial: NCT04468997
Drug: Drug 601
RxNorm normalized name: ethanol 0.601 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
Trial: NCT00862667
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00241939 300ug using Inhaler B
Trial: NCT03841630
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT03841630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03455842
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
Trial: NCT01668862
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
Trial: NCT01423747
Drug: VP16, ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
Trial: NCT01423747
Drug: VP16, ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
Trial: NCT01851759
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
Trial: NCT01716442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03198507
Drug: RHB-105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Trial: NCT00343460
Drug: APF530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given subcutanously
Trial: NCT03805152
Drug: Neuronox(R)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection botulinum toxin intramuscular for affected neck muscle
Trial: NCT03292796
Drug: Prostaglandins
RxNorm normalized name: PROSTAGLANDINS
DrugBank: Prostaglandin G2 (DB03866)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00700115
Drug: Pre-study antiretroviral regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of pre-study antiretroviral regimen
Trial: NCT01666041
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006340
Drug: arginine butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02549365
Drug: Live attenuated influenza vaccine
RxNorm normalized name: Live attenuated influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season